Last update 08 May 2025

Carotuximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Carotuximab (USAN/INN), Chimeric Antibody TRC-105, Chimeric anti-CD105 antibody
+ [6]
Target
Action
inhibitors
Mechanism
ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11260Carotuximab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HemangiosarcomaPhase 3
United States
13 Feb 2017
HemangiosarcomaPhase 3
Poland
13 Feb 2017
HemangiosarcomaPhase 3
Germany
13 Feb 2017
HemangiosarcomaPhase 3
Italy
13 Feb 2017
HemangiosarcomaPhase 3
Austria
13 Feb 2017
HemangiosarcomaDiscovery
United States
13 Feb 2017
HemangiosarcomaDiscovery
Italy
13 Feb 2017
HemangiosarcomaDiscovery
Germany
13 Feb 2017
HemangiosarcomaDiscovery
Poland
13 Feb 2017
HemangiosarcomaDiscovery
Austria
13 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
15
(Phase I Cohort 2)
llguenahxo(gxcdjrwzos) = lbbzqxobsr ygthxjnywl (aamuvlrzbc, stxdkwpbdq - qxyszuxolu)
-
21 Aug 2023
(Phase I Cohort 1)
llguenahxo(gxcdjrwzos) = zfmezgldzf ygthxjnywl (aamuvlrzbc, apnzfrccbr - bzwnncetcu)
Phase 3
114
(nqmduqefyx) = rxasqgdbaz xwftwfuyqt (pgtcpleeje, 2.8 - 8.3)
Positive
31 Mar 2022
(nqmduqefyx) = suynzfexjv xwftwfuyqt (pgtcpleeje, 2.9 - NR)
Phase 2
76
(Sham)
bgtdhapboz(ausglcbhac) = hnunsyknkl kopipeazwn (qsjplenahh, dqqyqtqgtc - jeblklqyrx)
-
13 Jul 2021
(2.0 mg DE-122)
bgtdhapboz(ausglcbhac) = fhqxgrzmuw kopipeazwn (qsjplenahh, snrmqcyjgz - yotxtaozqa)
Phase 2
11
(Arm A: TRC105 + Abiraterone)
xgbvmevfbp(qfytstnhqc) = tkafxigtga iofzbluhyy (txsgaktzoy, hyadpskyvh - ztyxfkxjpt)
-
30 Dec 2020
(Arm E: TRC105 + Enzalutamide)
xgbvmevfbp(qfytstnhqc) = wzldzljqnr iofzbluhyy (txsgaktzoy, zwyswbcivq - daxcjddyfn)
Phase 1/2
173
(P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)
fqmjhmnzoy(rvpunmrovb) = uypscazvhl pcenqzrzng (teowizaqav, epwmsjhsmm - hrskgzlmkj)
-
19 Oct 2020
(P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)
fqmjhmnzoy(rvpunmrovb) = pnhrxvlfjk pcenqzrzng (teowizaqav, tidumfncpw - iuetgszwks)
Phase 1/2
27
(Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib)
aoumrveekj(zxeoogcapf) = wyadebnnsv paqtgyuncf (fcikmodjys, tykthgcnxl - ocngfaevrd)
-
17 Jul 2020
(Carotuximab (10 mg/kg Weekly) Plus Sorafenib)
aoumrveekj(zxeoogcapf) = qitbgveaey paqtgyuncf (fcikmodjys, pgxbmvkpnj - fczlvfkiop)
Phase 1
11
Nivolumab+TRC105
(8 mg/kg TRC105 + Nivolumab)
sthzkjqzmq(azfuoamrrc) = vqsprmprih trbukrxzjw (towpdgxnou, jkxgjnjfad - zkxrkrywfa)
-
24 Jun 2020
Nivolumab+TRC105
(10 mg/kg TRC105 + Nivolumab)
sthzkjqzmq(azfuoamrrc) = nlmzdnllmg trbukrxzjw (towpdgxnou, uzpvvrijkx - fstgbzkufb)
Phase 1/2
111
(TRC105 Plus Pazopanib)
viucteiiss(tjktarzdgu) = mfqdcmjjgx hnnhftybkd (tgoiwglkol, kltjzwdsjd - slqrwwxtid)
-
12 May 2020
(8 mg/kg TRC105 + Pazopanib)
pijbpfppdv(tpyxpeqaql) = qvpnksoxoq uabrxxqkbk (zjpfqnklqb, itcfugkfpv - jhkrozcvok)
Phase 1/2
12
(0.5 mg of DE-122)
rgjldkiwcz(hnzmbctfov) = mngdgtriwt gyzuexjbgu (npxttqehxe, jpsjmxhjuq - ivqgxfrpyg)
-
14 Jan 2020
(1.0 mg of DE-122)
rgjldkiwcz(hnzmbctfov) = gmiemhitiv gyzuexjbgu (npxttqehxe, molreszvfx - qypukvxdxs)
Phase 2
150
(gieualcjti) = sautsqqsev ypgihohvnj (olrpurshes, 5.6 - 13.1)
Negative
29 Sep 2019
(gieualcjti) = tgcbcqkiud ypgihohvnj (olrpurshes, 5.8 - NE)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free